MoneyWorks4Me

Biocon informs about updates

22 Sep 2018 Evaluate

Biocon has informed that the US FDA conducted a periodic cGMP inspection of its Drug Substance manufacturing site at Bangalore Campus from Sep 17 - 21, 2018. The weeklong audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects the strong commitment to cGMP compliance.

The above information is a part of company’s filings submitted to BSE.


Peers
Company Name CMP
Sun Pharma. Inds. 1782.00
Dr. Reddys Labs. 1208.00
Cipla 1334.00
Lupin 2010.00
Zydus Lifesciences 1138.50
View more..